Patent extension requests
Executive Summary
FDA review periods for three drugs determined. Merck's Prinivil (lisinopril) had a review period of 2,373 days (1,751 during IND and 622 during NDA); Merck is seeking 676 days of patent extension. Sterling's Corotrope (milrinone lactate) review period was 2,205 days (1,287 during IND and 918 during NDA); the company is seeking 730 days of patent extension. Kendall McGaw's Ucephan (sodium benzoate) had a 2,871 day review (2,058 IND; 813 NDA). Kendall is also seeking 730 days of patent extension. The Patent Office makes the final determination of the length of extension.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.